title: OCF can repress tumor metastasis by inhibiting epithelial-mesenchymal transition involved in PTEN/PI3K/AKT pathway in lung cancer cells.
abstract: A component formula with definite compositions provides a new approach to treat various diseases. Salvia miltiorrhiza and Panax ginseng are widely used in China because of their antitumor properties. In the previous study, the optimizing component formula (OCF), prepared with salvianolic acids, ginsenosides, and ginseng polysaccharides (5, 10, and 5 mg·L-1, respectively) extracted from S. miltiorrhiza and P. ginseng on the basis of IC50 in lung cancer A549 cells and damage minimization on human bronchial epithelial cells in vitro. Currently, we also have demonstrated the inhibitory effect of OCF on A549 cell migration and invasion in vitro. According to Lewis lung cancer cells (LLC) allograft in C57BL/6 mice and A549 xenograft in nude mice experiment, we found that the anti-tumor and anti-metastasis effects of OCF treatment were related to the inhibition of epithelial-mesenchymal transition (EMT). Further studies showed that the inhibitory effect of OCF on EMT was associated with the PTEN/PI3K/AKT pathway. Therefore, all studies revealed that OCF could prevent cancer progression and tumor metastasis by inhibiting EMT involved PTEN/PI3K/AKT signaling pathway in lung cancer cells.
authors.affiliation: Department of Preclinical Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.
authors.forename: Ye
authors.identifier: http://orcid.org/0000-0003-4086-1107
authors.initials: Y
authors.lastname: Yang
authors.affiliation: Department of Preclinical Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.
authors.forename: Shuang
authors.initials: S
authors.lastname: Qiu
authors.affiliation: Department of Preclinical Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.
authors.forename: Lei
authors.initials: L
authors.lastname: Qian
authors.affiliation: Department of Preclinical Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.
authors.forename: Yuan
authors.initials: Y
authors.lastname: Tian
authors.affiliation: Department of Preclinical Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.
authors.forename: Yingna
authors.initials: Y
authors.lastname: Chen
authors.affiliation: Department of Preclinical Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.
authors.forename: Lei
authors.initials: L
authors.lastname: Bi
authors.affiliation: Department of Preclinical Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.
authors.forename: Weiping
authors.initials: W
authors.lastname: Chen
mesh_terms: D000072283:A549 Cells; D000818:Animals; D058750:Epithelial-Mesenchymal Transition / Q000187:drug effects*; D006801:Humans; D008175:Lung Neoplasms / Q000473:pathology*; D051379:Mice; D008810:Mice, Inbred C57BL; D009362:Neoplasm Metastasis / Q000517:prevention & control*; D051059:PTEN Phosphohydrolase / Q000378:metabolism*; D019869:Phosphatidylinositol 3-Kinases / Q000378:metabolism*; D010936:Plant Extracts / Q000494:pharmacology*; D051057:Proto-Oncogene Proteins c-akt / Q000378:metabolism*; D023041:Xenograft Model Antitumor Assays
chemical_list: D010936:Plant Extracts; D019869:Phosphatidylinositol 3-Kinases; D051057:Proto-Oncogene Proteins c-akt; D051059:PTEN Phosphohydrolase; C494929:PTEN protein, human